J'Onco Mentor Version 9.09 — STORE Manual Workspace

Desktop version. Mobile app coming.

WHAT IS J’ONCO MENTOR?LUNGBREASTHEAD & NECKPROSTATEENDOMETRIUMLIVERADRENAL GLANDKIDNEYTHYROIDBLADDERCOLON & RECTUMMELANOMA OF SKINPANCREASSTOMACHCNSHEMATOPOIETIC DISORDERSTOP CANCER SITESSTORE MANUALRADIATION GUIDESTATE REPORTABILITYICD-10-CM / SECONDARY DXODS RESOURCES
Standards driver

Diagnosis Year

Select the diagnosis year first. The STORE workspace uses it to identify the applicable standards cycle and to flag year-sensitive guidance.

No diagnosis year selected. Year-dependent STORE guidance should not be assumed.
Current standards context

STORE Standards Context

STORE Manual
—
NAACCR Cycle
—
Case Rules
—
STORE Section One

Case Eligibility & Reportability

CoC-required cases

Use STORE to determine which tumors must be accessioned, abstracted, followed, and submitted for CoC purposes. State/central registry requirements may be broader.

The CoC-required analytic population is based on Class of Case 00–22, subject to site/histology eligibility rules and diagnosis-year instructions.

Reportable by agreement

A cancer committee or central registry may request collection of tumors not otherwise required by the CoC. Follow the requesting standard setter for the extent of abstraction and follow-up.

Open State Reportability module →
Updated for STORE 2027

Ambiguous Terminology

References of last resort: use the ambiguous terminology list when the record is unclear and the physician/PAHP/pathologist cannot clarify the case. A clear statement of malignancy or tumor spread takes priority over the list.

Terms that constitute a diagnosis

Apparent(ly)
Appear(s)
Comparable (with)
Compatible (with)
Consistent (with)
Favors
Malignant appear(ing)
Most likely
Presum(ed)
Probable
Suspect(ed)
Suspicious (for)
Typical (of)

Do not constitute a diagnosis without additional information

Cannot be ruled out
Equivocal
Possible
Potentially malignant
Questionable
Rule out
Suggests
Worrisome
Likely
CNS exception: “Tumor” and “Neoplasm” may constitute a diagnosis for nonmalignant primary intracranial/CNS sites C70.0–C72.9 and C75.1–C75.3 for diagnoses beginning in 2004.

Ambiguous-Term Checker

—Select the documented wording.

Cytology Exception

—Complete the cytology fields.
Interactive guide

Class of Case

Select Diagnosis Year first. Beginning with diagnosis year 2027, Class of Case codes 11 and 12 are no longer available; cases that would previously have used 11/12 route to 13/14.
Suggested Class of Case
—

Complete the fields to generate a suggested class.

Use this as an educational decision aid. Resolve conflicts against the applicable diagnosis-year STORE manual and the collecting standard setter.
STORE item 580

Date of First Contact

Analytic case

Use the date the patient became analytic—when the case first qualifies as Class of Case 00–22.

Nonanalytic case

Use the date the nonanalytic status begins under the standard setter that requires the case.

Autopsy / pathology-only

Autopsy-only uses date of death. For state-required pathology-only Class 43, use specimen collection date unless later updated when the patient receives first-course treatment at the facility.

Outside specimen read at your facility: if the specimen was collected elsewhere and only read at your facility, that reading alone does not establish the CoC Date of First Contact. If the patient later receives first-course treatment at your facility, use the date the patient reports for treatment and review Class 21/22.
Coding principles

Cancer Identification

STORE 2027’s coding-principles section includes Primary Site, occult cervical lymph node, cutaneous head & neck carcinoma, hematopoietic/lymphoid cancers, Kaposi sarcoma, melanoma, ill-defined sites, and revising the original diagnosis.
AJCC / stage at diagnosis

Staging Principles

Use the site module

J’Onco Mentor disease modules contain diagnosis-year-aware AJCC schema routing and TNM input controls where applicable.

Open disease modules →

Clinical vs pathologic context

Keep clinical, pathologic, and posttherapy classifications distinct. Use the current AJCC system required for the selected diagnosis year and schema.

NCDB / AJCC resources ↗
First course of treatment

Treatment Coding

Surgery

First course surgery, site-specific surgery codes, margins, lymph node surgery, and reason for no surgery.

Radiation

Phase-specific treatment volume, modality, planning technique, dose, fractions, and treatment sequence.

Open Radiation Guide →

Systemic / Other

Chemotherapy, hormone therapy, immunotherapy, hematologic transplant/endocrine procedures, other treatment, and palliative care.

Outcomes

Follow-Up / Recurrence

Local recurrence

Recurrence in the initial primary organ.

Regional recurrence

Recurrence in an adjacent organ or lymph nodes draining the organ.

Distant recurrence

Recurrence in a location beyond regional.

STORE 2027 instructs that once the first recurrence or progression has been recorded, recurrence items are not updated further. The 2027 summary of changes also removed the prior “trocar recurrence” example and added the 15-year follow-up endpoint language for recurrence/progression and vital status.
ICD-10-CM

Secondary Diagnoses

STORE Secondary Diagnosis #1–10

Capture existing/preexisting medical conditions, factors influencing health status, and complications for treatment of this cancer using ICD-10-CM values according to the applicable STORE instructions.

J’Onco ICD-10-CM tool

Search codes and build the ten secondary-diagnosis slots in the dedicated module.

Open ICD-10-CM / Secondary DX →
Diagnosis year 2027+

2027 Changes — High-Impact Registry Items

Area2027 impact
Class of CaseCodes 11 and 12 are no longer available beginning with diagnosis year 2027; prior 11/12 situations route to 13/14 under the revised reporting-facility framework.
Date of First ContactGuidance was revised/clarified, including the outside-specimen scenario and the point at which a nonanalytic case becomes analytic.
Secondary DiagnosesInstructions were updated, including broader description language and additional source guidance.
Method of Detection — BreastInstructions were revised and clarified for 2027; the field remains diagnosis-year dependent.
Recurrence / Follow-UpTrocar recurrence wording was removed; follow-up language now explicitly references the 15-year endpoint for Disease Follow-up/First Recurrence-Progression and Vital Status.
Source linksSTORE 2027 added links to resources throughout the manual.
Authoritative references

Official Sources

\n\n